Phase Ib trial demonstrates manageable toxicity and antitumor activity in unresectable hepatocellular carcinoma, suggesting potential efficacy.
Lenvatinib plus pembrolizumab has promising antitumor activity in uHCC. Toxicities were manageable, with no unexpected safety signals.
No takes yet. Share an insight, caveat, or question.
Finn et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: